CSL Behring Submits BLA Requesting Approval Of Human Fibrinogen Concentrate For The Treatment Of Congenital Bleeding

CSL Behring announced today that it has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval to market its human fibrinogen concentrate in the United States for the treatment of congenital fibrinogen deficiency, a rare bleeding disorder resulting from deficiency of fibrinogen.

More: continued here

Filed under: Blood on July 22nd, 2008